Narcolepsy Clinical Trials

35 recruitingLast updated: June 18, 2026

There are 35 actively recruiting narcolepsy clinical trials across 17 countries. Studies span Phase 2, Not Applicable, Phase 3, Phase 1. Top locations include Cincinnati, Ohio, United States, Columbia, South Carolina, United States, Austin, Texas, United States. Updated daily from ClinicalTrials.gov.


Narcolepsy Trials at a Glance

35 actively recruiting trials for narcolepsy are listed on ClinicalTrialsFinder across 6 cities in 17 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Cincinnati, Columbia, and Austin. Lead sponsors running narcolepsy studies include Takeda, Alkermes, Inc., and Centessa Pharmaceuticals (UK) Limited.

Browse narcolepsy trials by phase

Treatments under study

About Narcolepsy Clinical Trials

Looking for clinical trials for Narcolepsy? There are currently 19 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Narcolepsy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Narcolepsy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 35 trials

Recruiting

WAKIX® (Pitolisant) Pregnancy Registry

Pregnancy RelatedNarcolepsy
Harmony Biosciences Management, Inc.1,329 enrolled1 locationNCT05536011
Recruiting
Phase 2

A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)

Narcolepsy Type 1
Takeda92 enrolled1 locationNCT07633301
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

Narcolepsy Type 2
Alkermes, Inc.176 enrolled15 locationsNCT07502443
Recruiting
Phase 1

A Trial to Test the Safety and Tolerability of Lu AH69593 in Adults That Are Healthy or Have Narcolepsy

Narcolepsy
H. Lundbeck A/S104 enrolled2 locationsNCT07613710
Recruiting
Phase 3

A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)

Narcolepsy Type 1
Alkermes, Inc.150 enrolled5 locationsNCT07540897
Recruiting
Phase 2Phase 3

A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence

Narcolepsy Type 1Narcolepsy Type 2
Centessa Pharmaceuticals (UK) Limited222 enrolled2 locationsNCT07598708
Recruiting
Phase 1

A Phase 1, First-in-human Study of VX-433

Narcolepsy Type 1 (NT1)
Vertex Pharmaceuticals Incorporated118 enrolled1 locationNCT07584434
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

Narcolepsy Type 1
Alkermes, Inc.150 enrolled17 locationsNCT07455383
Recruiting
Not Applicable

Deciphering the Interactions Between Food Intake, Sleepiness, and Nighttime Sleep Quality in Patients With Type 1 Narcolepsy and Idiopathic Hypersomnia

Idiopathic HypersomniaNarcolepsy Type 1
Hospices Civils de Lyon76 enrolled2 locationsNCT06484348
Recruiting
Not Applicable

Evaluation of Social Cognition in Patient With Type 1 or Type 2 Narcolepsy Versus Patients With Idiopathic Hypersomnia

Social CognitionNarcolepsy
Centre Hospitalier Universitaire, Amiens75 enrolled1 locationNCT05773872
Recruiting
Phase 2

A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)

Narcolepsy Type 2
Takeda88 enrolled52 locationsNCT06952699
Recruiting

Epidemiology of Narcolepsy Type 1 and Type 2 in Spain

Narcolepsy Type 1Narcolepsy Type 2
Takeda100 enrolled10 locationsNCT07299097
Recruiting
Phase 2

A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy

Narcolepsy
Eisai Inc.64 enrolled57 locationsNCT07493265
Recruiting
Phase 3

A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy

Narcolepsy Type 1 (NT1)Narcolepsy With Cataplexy
Takeda88 enrolled18 locationsNCT07363720
Recruiting
Not Applicable

Pain Assessment in Patients With Idiopathic Rapid Eye Movement (REM) Sleep Behaviour Disorder

REM Sleep Behavior Disorder (iRBD)Narcolepsy Type 1
University Hospital, Toulouse24 enrolled1 locationNCT07365566
Recruiting
Phase 2

A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

Idiopathic HypersomniaNarcolepsy Type 1Narcolepsy Type 2
Centessa Pharmaceuticals (UK) Limited248 enrolled37 locationsNCT06752668
Recruiting
Phase 2

A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

Idiopathic HypersomniaNarcolepsy Type 1Narcolepsy Type 2
Centessa Pharmaceuticals (UK) Limited90 enrolled24 locationsNCT07096674
Recruiting

Proteomics and Metabolomics of Body Fluid in Patients With Narcolepsy

Narcolepsy
Qilu Hospital of Shandong University60 enrolled1 locationNCT06279247
Recruiting
Phase 2Phase 3

A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

Narcolepsy Type 1
Takeda500 enrolled52 locationsNCT05816382
Recruiting
Phase 2Phase 3

A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia

Idiopathic HypersomniaNarcolepsy Type 1Narcolepsy Type 2
Alkermes, Inc.256 enrolled46 locationsNCT06767683